Penn immunotherapy pioneer elected to National Academy of Inventors

December 19, 2016

PHILADELPHIA-- Yvonne J. Paterson, PhD, a professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, has been elected a fellow of the National Academy of Inventors. Fellows are named inventors on U.S. patents. Election to fellow status recognizes academic inventors who have "demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society." She joins 174 other leaders of academic invention in election to fellow status in the 2016 class.

Paterson, a breast cancer survivor, works to harness the body's immune system to provide protection against, and find cures for, cancer. She has been issued 32 U.S. patents and numerous foreign patents; a further 12 possible U.S. patents are under review.

Among her achievements, she led the development and testing of a cancer vaccine that uses the common bacterium Listeria monocytogenes, which can cause food poisoning and other illnesses, to fight tumors. "Unfortunately, our immune system doesn't recognize cancer cells as invaders," Paterson said. "So the goal is to exploit the bacterium, which the body does recognize as abnormal, into provoking the type of immune response necessary for wiping out the cancer cells and keeping them from coming back."

Paterson genetically modifies listeria to smuggle in proteins that can rouse the immune system into action. (Genetic modification also reduces the bacterium's adverse symptoms in the patient.) She then uses the made-to-order listeria to mimic an infection in the cancer cells, prompting an immune response from the body that seeks to eradicate the contamination. In addition to destroying tumor cells, the hope is that the immunotherapy can prevent metastatic cells from developing and spreading the cancer elsewhere in the body.

The research has resulted in the formation of two US companies, one of which, Advaxis, is in phase 3 clinical trials for this immunotherapy for cervical cancer, as well as earlier-stage trials for several more forms of cancer. Other potential targets include lung, prostate, head and neck, anal, breast, and gastric cancers, as well as melanoma and lymphoma.

"In principle, this could be used against virtually any cancer," says Paterson. Additionally, in partnership with the Penn School of Veterinary Medicine, use of the therapy is generating positive results against bone cancer in dogs--adding as much as five years of extra, tumor-free living.

Paterson has published over 100 peer-reviewed scholarly papers and more than 60 book chapters and reviews. Her honors include recognition as "one of the 100-most inspiring people in the life sciences industry" by PharmaVOICE, while her company Advaxis has received awards from the World Vaccine Congress, Farrah Fawcett Foundation, and Sarcoma Foundation of America. Paterson is an elected fellow of the American Association for the Advancement of Science and the American Society for Microbiology.

Born in the United Kingdom, she received her BSc and MSc in biochemistry from the University of Manchester, BA in mathematics and philosophy from Australian National University, and PhD in biochemistry from Melbourne University.

The National Academy of Inventors' 2016 fellows will be inducted on April 6, 2017, as part of the organization's sixth annual conference at the John F. Kennedy Presidential Library & Museum in Boston, MA. U.S. Commissioner for Patents Andrew H. Hirshfeld will provide the keynote address for the induction ceremony. In honor of their accomplishments, fellows will be presented with a trophy, medal, and rosette pin.
-end-
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.

University of Pennsylvania School of Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.